论文部分内容阅读
目的分析探讨美托洛尔与卡维地洛治疗慢性心力衰竭患者的临床疗效。方法 58例慢性心力衰竭患者,随机分为实验组和对照组,每组29例。对照组患者采取美托洛尔治疗,实验组患者采用卡维地洛治疗。观察两组患者的治疗效果和心功能恢复情况。结果 1年观察期间,对照组20例(68.97%)因心力衰竭加重再次进入本院重新治疗,实验组10例(34.48%)因心力衰竭加重再次进入本院重新治疗,实验组因心力衰竭加重再次进入本院重新治疗所占比例低于对照组,差异有统计学意义(P<0.05)。1年观察期间,对照组7例(24.14%)因心力衰竭恶化死亡,实验组4例(13.79%)因心力衰竭恶化死亡,两组因心力衰竭恶化死亡所占比例比较差异无统计学意义(P>0.05)。对照组治疗后纽约心脏病协会(NYHA)心功能分级较治疗前恶化,治疗前后比较差异具有统计学意义(P<0.05)。实验组治疗前后NYHA心功能分级比较差异无统计学意义(P>0.05)。结论慢性心力衰竭患者服用卡维地洛治疗,可使心力衰竭患者临床心功能得到稳定,显著降低因心力衰竭恶化所致再住院率,提高生活质量。
Objective To investigate the clinical efficacy of metoprolol and carvedilol in patients with chronic heart failure. Methods 58 patients with chronic heart failure were randomly divided into experimental group and control group, with 29 cases in each group. Patients in the control group were treated with metoprolol, and patients in the experimental group were treated with carvedilol. The therapeutic effect and recovery of cardiac function in two groups were observed. Results In the observation period of one year, 20 patients (68.97%) in the control group re-entered the hospital for re-treatment due to the worsening of heart failure. Ten patients (34.48%) in the experimental group re-entered the hospital for re-treatment due to the worsening of heart failure. Re-entering the hospital re-treatment accounted for a lower proportion of the control group, the difference was statistically significant (P <0.05). During the 1-year observation period, 7 patients (24.14%) died of heart failure in the control group, 4 patients (13.79%) died of heart failure in the experimental group, and there was no significant difference in the proportion of death due to worsening of heart failure between the two groups P> 0.05). The heart function of New York Heart Association (NYHA) after treatment in the control group was worse than that before treatment, and the difference was statistically significant before and after treatment (P <0.05). There was no significant difference in NYHA functional class before and after treatment in experimental group (P> 0.05). Conclusion Carvedilol treatment in patients with chronic heart failure can stabilize the clinical cardiac function in patients with heart failure, significantly reduce the rehospitalization rate due to worsening heart failure, and improve the quality of life.